loading page

Harnessing Chimeric Antigen Receptor (CAR)- expressing Treg to treat autoimmune related disorders
  • Fatemeh Rezaei Kahmini,
  • Shahab Shahgaldi
Fatemeh Rezaei Kahmini
Shiraz University of Medical Sciences

Corresponding Author:[email protected]

Author Profile
Shahab Shahgaldi
Tarbiat Modares University Faculty of Medical Sciences
Author Profile


Cellular therapy with regulatory T lymphocytes (Tregs) has attracted much attention in recent years due to their unique suppression properties. This feature makes them an ideal candidate to treat autoimmune related disorders. In recent years there are many studies that investigated the therapeutic effect of adaptive transfer of Treg in autoimmune disease. However, the results of these studies strongly suggest that antigen-specific Tregs have more superior beneficial effect compared to polyclonal Tregs. So, harnessing chimeric antigen receptor (CAR) technology to create antigen-specific engineered Treg that showed the ability to effectively migrate to damaged tissue and act more specifically to target antigens might hold great hope for treating autoimmune related disorders. In this mini-review, we discuss the potential of CAR-Treg to induce immune tolerance and their potential applications to treat autoimmune related disorders. And then we highlight the major challenges that should be addressed before clinical application.